{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T15:28:11Z","timestamp":1778254091527,"version":"3.51.4"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T00:00:00Z","timestamp":1765843200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002329","name":"Bundesamt f\u00fcr Gesundheit","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002329","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["JUVABIS22W0"],"award-info":[{"award-number":["JUVABIS22W0"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["HOBBIE19I0"],"award-info":[{"award-number":["HOBBIE19I0"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eBioMedicine"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.ebiom.2025.106103","type":"journal-article","created":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T13:50:05Z","timestamp":1767189005000},"page":"106103","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Multicentre preclinical profiling of apramycin for the treatment of nontuberculous mycobacteria"],"prefix":"10.1016","volume":"123","author":[{"given":"Minh-Vu H.","family":"Nguyen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel","family":"Plattner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deepshikha","family":"Verma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramya V.","family":"Krishnamurthy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vinicius","family":"Calado Nogueira de Moura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Klara","family":"Haldimann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramon","family":"Lang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katja","family":"Becker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Parvinder","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Radha Krishan","family":"Shandil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mayas","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5396-911X","authenticated-orcid":false,"given":"Zackery P.","family":"Bulman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Dick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shridhar","family":"Narayanan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bettina","family":"Schulthess","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2288-077X","authenticated-orcid":false,"given":"Satoshi","family":"Mitarai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles L.","family":"Daley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9205-0384","authenticated-orcid":false,"given":"Sven N.","family":"Hobbie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ebiom.2025.106103_bib1","doi-asserted-by":"crossref","first-page":"303","DOI":"10.3389\/fimmu.2020.00303","article-title":"The rise of non-tuberculosis mycobacterial lung disease","volume":"11","author":"Ratnatunga","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.ebiom.2025.106103_bib2","article-title":"The impact of nontuberculous mycobacteria species on mortality in patients with nontuberculous mycobacterial lung disease","volume":"13","author":"Wang","year":"2022","journal-title":"Front Microbiol"},{"issue":"4","key":"10.1016\/j.ebiom.2025.106103_bib3","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1093\/cid\/ciaa1125","article-title":"Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS\/ERS\/ESCMID\/IDSA clinical practice guideline","volume":"71","author":"Daley","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.ebiom.2025.106103_bib4","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.rmed.2006.04.002","article-title":"A double-blind randomized study of aminoglycoside infusion with combined therapy for pulmonary Mycobacterium avium complex disease","volume":"101","author":"Kobashi","year":"2007","journal-title":"Respir Med"},{"issue":"3","key":"10.1016\/j.ebiom.2025.106103_bib5","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.chest.2021.03.070","article-title":"Amikacin liposome inhalation suspension for refractory Mycobacterium avium complex lung disease: sustainability and durability of culture conversion and safety of long-term exposure","volume":"160","author":"Griffith","year":"2021","journal-title":"Chest"},{"issue":"4","key":"10.1016\/j.ebiom.2025.106103_bib6","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.1093\/cid\/ciae421","article-title":"Nontuberculous mycobacterial pulmonary disease: patients, principles, and prospects","volume":"79","author":"Nguyen","year":"2024","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ebiom.2025.106103_bib7","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1093\/jac\/dkad317","article-title":"In vitro susceptibility patterns for slowly growing non-tuberculous mycobacteria in the USA from 2018 to 2022","volume":"78","author":"Calado Nogueira de Moura","year":"2023","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"10.1016\/j.ebiom.2025.106103_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.diagmicrobio.2022.115882","article-title":"In vitro susceptibility patterns for rapidly growing nontuberculous mycobacteria in the United States","volume":"105","author":"Hunkins","year":"2023","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"11","key":"10.1016\/j.ebiom.2025.106103_bib9","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1086\/420742","article-title":"Aminoglycoside toxicity: daily versus thrice-weekly dosing for treatment of mycobacterial diseases","volume":"38","author":"Peloquin","year":"2004","journal-title":"Clin Infect Dis"},{"issue":"10","key":"10.1016\/j.ebiom.2025.106103_bib10","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1093\/jac\/dkac225","article-title":"Population pharmacokinetics of apramycin from first-in-human plasma and urine data to support prediction of efficacious dose","volume":"77","author":"Zhao","year":"2022","journal-title":"J Antimicrob Chemother"},{"issue":"2","key":"10.1016\/j.ebiom.2025.106103_bib11","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01510-21","article-title":"Apramycin overcomes the inherent lack of antimicrobial bactericidal activity in Mycobacterium abscessus","volume":"66","author":"Selchow","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.ebiom.2025.106103_bib12","doi-asserted-by":"crossref","first-page":"265","DOI":"10.4103\/ijmy.ijmy_73_18","article-title":"Antimycobacterial activity of veterinary antibiotics (Apramycin and Framycetin) against Mycobacterium abscessus: implication for patients with cystic fibrosis","volume":"7","author":"Moore","year":"2018","journal-title":"Int J Mycobacteriol"},{"issue":"1","key":"10.1016\/j.ebiom.2025.106103_bib13","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1038\/s41598-019-38634-3","article-title":"Lower ototoxicity and absence of hidden hearing loss point to gentamicin C1a and apramycin as promising antibiotics for clinical use","volume":"9","author":"Ishikawa","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.ebiom.2025.106103_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103652","article-title":"Antibacterial activity of apramycin at acidic pH warrants wide therapeutic window in the treatment of complicated urinary tract infections and acute pyelonephritis","volume":"73","author":"Becker","year":"2021","journal-title":"eBioMedicine"},{"issue":"27","key":"10.1016\/j.ebiom.2025.106103_bib15","doi-asserted-by":"crossref","first-page":"10984","DOI":"10.1073\/pnas.1204073109","article-title":"Dissociation of antibacterial activity and aminoglycoside ototoxicity in the 4-monosubstituted 2-deoxystreptamine apramycin","volume":"109","author":"Matt","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ebiom.2025.106103_bib16","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/j.cmi.2022.05.003","article-title":"Translational in vitro and in vivo PKPD modelling for apramycin against Gram-negative lung pathogens to facilitate prediction of human efficacious dose in pneumonia","volume":"28","author":"Aranzana-Climent","year":"2022","journal-title":"Clin Microbiol Infect"},{"issue":"9","key":"10.1016\/j.ebiom.2025.106103_bib17","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/j.cmi.2020.12.004","article-title":"Efficacy of EBL-1003 (apramycin) against Acinetobacter baumannii lung infections in mice","volume":"27","author":"Becker","year":"2021","journal-title":"Clin Microbiol Infect"},{"issue":"4","key":"10.1016\/j.ebiom.2025.106103_bib18","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1002\/cpt.2104","article-title":"Model-Informed drug development for antimicrobials: translational PK and PK\/PD modeling to predict an efficacious human dose for apramycin","volume":"109","author":"Sou","year":"2021","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ebiom.2025.106103_bib19","series-title":"Susceptibility Testing of Mycobacteria, Nocardia spp., and other Aerobic Actinomycetes--Third Edition: M24","year":"2018"},{"key":"10.1016\/j.ebiom.2025.106103_bib20","series-title":"Performance Standards for Susceptibility Testing of Mycobacteria, Nocardia spp., and Other Aerobic Actinomycetes--Second Edition: M24S","year":"2023"},{"issue":"5","key":"10.1016\/j.ebiom.2025.106103_bib21","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1111\/j.1469-0691.2006.01377.x","article-title":"Statistical characterisation of bacterial wild-type MIC value distributions and the determination of epidemiological cut-off values","volume":"12","author":"Turnidge","year":"2006","journal-title":"Clin Microbiol Infect"},{"issue":"5","key":"10.1016\/j.ebiom.2025.106103_bib22","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0010777","article-title":"Optimisation of bioluminescent reporters for use with mycobacteria","volume":"5","author":"Andreu","year":"2010","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.ebiom.2025.106103_bib23","doi-asserted-by":"crossref","DOI":"10.1128\/mbio.00598-23","article-title":"A novel tool to identify bactericidal compounds against vulnerable targets in drug-tolerant M. tuberculosis found in Caseum","volume":"14","author":"Sarathy","year":"2023","journal-title":"mBio"},{"issue":"9","key":"10.1016\/j.ebiom.2025.106103_bib24","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00381-23","article-title":"ADP-ribosylation-resistant rifabutin analogs show improved bactericidal activity against drug tolerant M. abscessus in caseum surrogate","volume":"67","author":"Xie","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ebiom.2025.106103_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fitd.2024.1413211","article-title":"Apramycin kills replicating and non-replicating Mycobacterium tuberculosis","volume":"5","author":"Kaur","year":"2024","journal-title":"Front Trop Dis"},{"issue":"1","key":"10.1016\/j.ebiom.2025.106103_bib26","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1128\/AAC.39.1.34","article-title":"Macromolecular mechanisms of sputum inhibition of tobramycin activity","volume":"39","author":"Hunt","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"10.1016\/j.ebiom.2025.106103_bib27","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1093\/jac\/dky546","article-title":"In vitro activity of apramycin against multidrug-carbapenem- and aminoglycoside-resistant Enterobacteriaceae and Acinetobacter baumannii","volume":"74","author":"Juhas","year":"2019","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"10.1016\/j.ebiom.2025.106103_bib28","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.jcf.2019.05.013","article-title":"Clofazimine inhalation suspension for the aerosol treatment of pulmonary nontuberculous mycobacterial infections","volume":"18","author":"Banaschewski","year":"2019","journal-title":"J Cyst Fibros"},{"issue":"7","key":"10.1016\/j.ebiom.2025.106103_bib29","doi-asserted-by":"crossref","first-page":"e178","DOI":"10.1016\/S1473-3099(21)00586-7","article-title":"Consensus management recommendations for less common non-tuberculous mycobacterial pulmonary diseases","volume":"22","author":"Lange","year":"2022","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"10.1016\/j.ebiom.2025.106103_bib30","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1093\/jac\/dkaf073","article-title":"Pharmacodynamic assessment of apramycin against Mycobacterium abscessus in a hollow fibre infection model","volume":"80","author":"Singh","year":"2025","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"10.1016\/j.ebiom.2025.106103_bib31","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.cmi.2023.02.007","article-title":"Towards clinical breakpoints for non-tuberculous mycobacteria - determination of epidemiological cut off values for the Mycobacterium avium complex and Mycobacterium abscessus using broth microdilution","volume":"29","author":"Fr\u00f6berg","year":"2023","journal-title":"Clin Microbiol Infect"},{"issue":"1","key":"10.1016\/j.ebiom.2025.106103_bib32","doi-asserted-by":"crossref","first-page":"6108","DOI":"10.1038\/s41598-021-85721-5","article-title":"Association between 16S rRNA gene mutations and susceptibility to amikacin in Mycobacterium avium complex and Mycobacterium abscessus clinical isolates","volume":"11","author":"Kim","year":"2021","journal-title":"Sci Rep"},{"issue":"6","key":"10.1016\/j.ebiom.2025.106103_bib33","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1086\/515328","article-title":"A single 16S ribosomal RNA substitution is responsible for resistance to amikacin and other 2-deoxystreptamine aminoglycosides in Mycobacterium abscessus and Mycobacterium chelonae","volume":"177","author":"Prammananan","year":"1998","journal-title":"J Infect Dis"},{"issue":"1","key":"10.1016\/j.ebiom.2025.106103_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2024.107181","article-title":"Apramycin efficacy against carbapenem- and aminoglycoside-resistant Escherichia coli and Klebsiella pneumoniae in murine bloodstream infection models","volume":"64","author":"Frimodt-M\u00f8ller","year":"2024","journal-title":"Int J Antimicrob Agents"},{"issue":"8","key":"10.1016\/j.ebiom.2025.106103_bib35","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.biochi.2006.04.008","article-title":"A genetic model to investigate drug-target interactions at the ribosomal decoding site","volume":"88","author":"Hobbie","year":"2006","journal-title":"Biochimie"},{"issue":"8","key":"10.1016\/j.ebiom.2025.106103_bib36","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1093\/jac\/dkx125","article-title":"Elucidation of Mycobacterium abscessus aminoglycoside and capreomycin resistance by targeted deletion of three putative resistance genes","volume":"72","author":"Rominski","year":"2017","journal-title":"J Antimicrob Chemother"},{"issue":"6","key":"10.1016\/j.ebiom.2025.106103_bib37","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1021\/acsinfecdis.5b00036","article-title":"Comparative study of Eis-like enzymes from pathogenic and Nonpathogenic bacteria","volume":"1","author":"Green","year":"2015","journal-title":"ACS Infect Dis"},{"key":"10.1016\/j.ebiom.2025.106103_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.tube.2024.102503","article-title":"Preclinical murine models for the testing of antimicrobials against Mycobacterium abscessus pulmonary infections: current practices and recommendations","volume":"147","author":"Dartois","year":"2024","journal-title":"Tuberculosis (Edinb)"}],"container-title":["eBioMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396425005535?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396425005535?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T03:02:00Z","timestamp":1773975720000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352396425005535"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":38,"alternative-id":["S2352396425005535"],"URL":"https:\/\/doi.org\/10.1016\/j.ebiom.2025.106103","relation":{},"ISSN":["2352-3964"],"issn-type":[{"value":"2352-3964","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multicentre preclinical profiling of apramycin for the treatment of nontuberculous mycobacteria","name":"articletitle","label":"Article Title"},{"value":"eBioMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ebiom.2025.106103","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106103"}}